SEC Form 4/A · accession 0001192482-18-000224
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Brian Piper
Officer — CFO & Corporate Secretary
Period of report
Aug 11, 2017
Accepted (ET)
May 16, 2018 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F2,F1 | $1.32 | Aug 11, 2017 | A | 110,000 | A | — | Aug 11, 2027 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer.
- F2Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations.